05/13/2017

A novel immunotherapy to fight bladder cancer

 

A new drug to fight bladder cancer:

The experimental results of P-MAPA immunotherapy 

                                                                                   Farmabrasilis Research Team

January 2018    

Based on experimental data and a scientific rationale, the research network Farmabrasilis announces P-MAPA - an immunotherapy in late-stage development - as an alternative to treat bladder cancer patients in five specific conditions that arise in the course of disease and treatments, and is looking for patient advocates, bladder cancer advocacy networks, research groups, institutions and pharmaceutical companies interested in establishing collaborations to move forward this novel therapy for bladder cancer.

P-MAPA has shown an impressive antitumor activity and a clear superiority over BCG, the standard treatment for bladder cancer, in comparative preclinical studies of efficacy and safety. As evidenced in animal models of bladder cancer, P-MAPA can help to overcome the BCGs lack of effectivity and toxicity. The toxicity of P-MAPA in the urothelium at therapeutic dosage is close to zero.

The Farmabrasilis Research Team argues that P-MAPA immunotherapy represents a novel approach to fight high-grade malignant lesions still in the urinary bladder, before they spread to adjacent tissues and organs. P-MAPA monotherapy could be used for treatment of non-invasive bladder cancer and also in association with other drugs for advanced forms of the disease, without additional toxicity.

The five specific conditions in which P-MAPA could be used, helping to solve urgent unmet medical needs, are:

● Condition 1: Patients with high-grade non-muscle invasive bladder cancer (NMIBC) at high risk of recurrence and disease progression who are BCG-refractory or BCG-relapsing.

● Condition 2: Patients with high-grade NMIBC at high risk of recurrence and disease progression who are BCG-intolerant.

● Condition 3: Patients with high-grade NMIBC who are BCG-refractory or BCG-relapsing, for whom cystectomy would be associated with high morbidity or mortality.

● Condition 4: Patients with high-grade NMIBC, BCG-refractory and BCG-relapsing, at high risk of recurrence and progression, for whom cystectomy would be associated with high morbidity or mortality, and who are refractory to Valrubicin as second-line therapy. 

● Condition 5: Patients with locally advanced and metastatic bladder cancer.

 

 

See the full scientific rationale at: P-MAPA SCIENTIFIC RATIONALE 

 

 

PubMed database for P-MAPA:  

 

https://www.ncbi.nlm.nih.gov/pubmed/?term=p-mapa

 

 

Contact: 

Iseu Nunes

Patient advocate

Farmabrasilis CEO